Spironolactone and hair loss is a topic of growing interest among women seeking treatment for female-pattern hair loss (FPHL) in the UK. Originally developed as a potassium-sparing diuretic, spironolactone has anti-androgenic properties that make it useful in slowing androgen-driven follicle miniaturisation. Although it is not licensed by the MHRA specifically for hair loss, it is prescribed off-label by NHS dermatologists and specialists as part of individualised, evidence-informed care. This article explains how spironolactone works, who may be suitable, what the evidence shows, and how it compares with other treatments available in the UK.

How Spironolactone Works for Hair Loss

Spironolactone reduces androgenic signalling at hair follicles by competitively blocking androgen receptors, slowing the follicle miniaturisation that drives female-pattern hair loss. Its use for this indication is off-label in the UK.

Not sure if this is normal? Chat with one of our pharmacists →

Spironolactone is a potassium-sparing diuretic that has been used for decades to manage conditions such as heart failure, hypertension, and fluid retention. Its role in treating hair loss stems from a separate pharmacological property: anti-androgenic activity. Spironolactone works primarily by competitively blocking androgen receptors, thereby reducing the effect of male sex hormones — such as testosterone and dihydrotestosterone (DHT) — on target tissues. It also has a modest inhibitory effect on androgen synthesis and 5α-reductase activity, though androgen receptor antagonism is considered its principal mechanism.

In androgenetic alopecia (commonly known as female-pattern hair loss, or FPHL), androgen sensitivity in genetically susceptible hair follicles causes them to progressively miniaturise, producing finer, shorter hairs and eventually leading to visible thinning. It is important to note that FPHL can occur even when circulating androgen levels are within the normal range; the condition reflects follicular sensitivity rather than necessarily elevated androgens. By reducing androgenic signalling at the follicle, spironolactone may slow this process and, in some cases, support partial regrowth — though response is variable.

Spironolactone is not licensed by the MHRA specifically for hair loss in the UK. Its use in this context is considered 'off-label', meaning it is prescribed at the clinical judgement of a doctor based on available evidence, in accordance with GMC guidance on prescribing unlicensed and off-label medicines. This does not mean it is unsafe — off-label prescribing is a well-established and legal practice within the NHS — but patients should be aware of this distinction and should have the opportunity to discuss the risks and benefits with their clinician before starting treatment.

Key UK references: emc SmPC for spironolactone; BNF: Spironolactone; GMC Good practice in prescribing and managing medicines and devices.

Who May Be Prescribed Spironolactone for Hair Loss in the UK

Spironolactone for hair loss is primarily considered for adult women with female-pattern hair loss who have not responded adequately to topical minoxidil, and is generally avoided in men due to feminising side effects.

Experiencing these side effects? Our pharmacists can help you navigate them →

In the UK, spironolactone for hair loss is primarily considered for adult women experiencing androgenetic alopecia or diffuse hair thinning. It is generally not recommended for men with hair loss due to the risk of feminising side effects, including gynaecomastia (breast tissue development) and sexual dysfunction, though this is a clinical judgement rather than an absolute rule.

Women who may be considered suitable candidates include those who:

• Have been diagnosed with female-pattern hair loss (FPHL) confirmed by a GP or dermatologist

• Have not responded adequately to first-line treatments such as topical minoxidil

• Show clinical or biochemical signs of androgen excess — noting that androgen blood tests (e.g., testosterone, DHEAS) are generally indicated only when there are clinical features of hyperandrogenism (such as hirsutism, acne, or menstrual irregularity), rather than routinely in all FPHL

• Are not pregnant, planning pregnancy, or breastfeeding

Spironolactone is contraindicated in pregnancy due to the risk of feminisation of a male foetus. Women of childbearing potential are strongly advised to use reliable contraception throughout treatment; clinicians will typically discuss this in detail, document the counselling, and may recommend a baseline pregnancy test before initiating treatment. Spironolactone is generally avoided during breastfeeding for this off-label indication; women should discuss their individual circumstances with their prescriber, who will weigh the risks and benefits in line with SmPC and NHS guidance.

Women with polycystic ovary syndrome (PCOS), a condition frequently associated with elevated androgens and hair thinning, may be particularly suitable candidates, as spironolactone may address both the hormonal imbalance and associated hair loss.

Patients should be aware of red flags that warrant prompt referral to a dermatologist or endocrinologist, including: rapid or sudden onset of hair loss, signs of virilisation (e.g., deepening voice, clitoromegaly), suspected scarring alopecia, or hair loss associated with systemic symptoms. Prescribing decisions for spironolactone are typically made by, or in consultation with, a consultant dermatologist or endocrinologist.

Key UK references: PCDS Female Pattern Hair Loss guidance; BNF: Spironolactone; NHS Medicines A–Z: Spironolactone; GMC Good practice in prescribing and managing medicines and devices.

What the Evidence Says About Effectiveness

Available evidence — largely from observational studies and retrospective analyses — suggests spironolactone can stabilise or modestly improve hair density in women with FPHL, though large-scale RCT evidence remains limited.

The evidence base for spironolactone in treating female hair loss is growing, though it remains largely derived from observational studies, retrospective analyses, and small clinical trials rather than large-scale randomised controlled trials (RCTs). High-quality RCT evidence specifically for spironolactone in FPHL is limited, and this should be acknowledged when discussing treatment expectations.

Available published data — including retrospective case series and systematic reviews — broadly suggest that a meaningful proportion of women with FPHL treated with spironolactone experience stabilisation or some improvement in hair density over 6–12 months, though reported response rates vary considerably between studies and should be interpreted with caution given methodological limitations. Similar findings have been reported in studies examining women with PCOS-related hair loss.

Direct head-to-head comparisons between spironolactone and other treatments such as minoxidil are limited. Some clinicians use both agents concurrently, as they act via different mechanisms and may offer complementary benefits. Observational data suggest that combining oral minoxidil with spironolactone may be beneficial for some women with FPHL, though robust RCT evidence to confirm superiority over monotherapy is not yet established, and further research is needed.

NICE does not currently have a specific guideline on the management of androgenetic alopecia in women, and spironolactone is not formally included in NHS treatment pathways for hair loss. However, it is used within NHS dermatology departments and private clinics as part of evidence-informed, individualised care, consistent with guidance from the Primary Care Dermatology Society (PCDS) and the British Association of Dermatologists (BAD). Patients should have realistic expectations: spironolactone is more likely to slow progression than to fully restore lost hair.

Key UK references: PCDS Female Pattern Hair Loss guidance; BAD patient information on Female Pattern Hair Loss; peer-reviewed systematic reviews of spironolactone for FPHL.

Dosage, Duration, and What to Expect During Treatment

Treatment typically starts at 25–50 mg daily, titrating to a maintenance dose of 100–200 mg; meaningful improvement is unlikely before 3–6 months, with full response assessed at 6–12 months.

Spironolactone for hair loss is typically initiated at a low dose of 25–50 mg daily, with gradual titration upwards depending on tolerability and clinical response. Most dermatologists aim for a maintenance dose in the range of 100–200 mg per day, though individual regimens vary based on the patient's medical history, blood pressure, and renal function.

Spironolactone should generally be avoided if eGFR is below 30 mL/min/1.73 m² or if baseline serum potassium exceeds 5.0 mmol/L. Caution and dose review are warranted if eGFR is between 30 and 45 mL/min/1.73 m². Clinicians will assess renal function and electrolytes before initiating treatment.

Patients should be aware that hair loss treatments generally require patience. Meaningful improvement in hair density or a reduction in shedding is unlikely to be apparent before 3–6 months of consistent treatment. Full assessment of response is usually made at the 6–12 month mark. If there is no discernible benefit after 12 months at an adequate dose, discontinuation or a change in approach is typically considered.

During treatment, the following monitoring is generally recommended:

• Baseline: renal function (eGFR), serum electrolytes (particularly potassium), blood pressure, and — in women of childbearing potential — a pregnancy test

• Ongoing: electrolytes and renal function at approximately 4–8 weeks after initiation or dose change, then periodically thereafter, with frequency guided by individual risk factors

• Blood pressure checks: spironolactone can lower blood pressure, which may cause dizziness, particularly in those already taking antihypertensive medication

Women of childbearing potential must use effective contraception throughout treatment. If pregnancy is suspected or confirmed, spironolactone should be stopped immediately and medical advice sought without delay.

Interactions and substances to avoid or use with caution:

• ACE inhibitors, angiotensin receptor blockers (ARBs), and other potassium-sparing diuretics — increased risk of hyperkalaemia

• Trimethoprim and co-trimoxazole — increased risk of hyperkalaemia

• Potassium supplements and potassium-containing salt substitutes — avoid unless specifically directed by a clinician

• Heparins (including low molecular weight heparins) — may increase potassium

• Ciclosporin and tacrolimus — increased risk of hyperkalaemia

• NSAIDs (e.g., ibuprofen, naproxen): regular or high-dose use should be avoided without medical advice, as these can reduce the efficacy of spironolactone and increase the risk of renal impairment and electrolyte disturbance; occasional use at recommended doses carries lower risk, but patients should seek guidance from their clinician or pharmacist

• Digoxin: spironolactone may interfere with some digoxin assays; inform the laboratory if monitoring digoxin levels

Key UK references: emc SmPC for spironolactone; BNF: Spironolactone; NHS Medicines A–Z: Spironolactone.

Side Effects and Safety Considerations

The most common side effects are menstrual irregularities, breast tenderness, dizziness, and increased urinary frequency; hyperkalaemia is a serious risk requiring monitoring, and the drug is contraindicated in pregnancy.

Spironolactone is generally well tolerated at the doses used for hair loss, but patients should be informed of potential side effects before commencing treatment. The most commonly reported include:

• Menstrual irregularities: including irregular periods, spotting between periods, or changes in cycle length — these are among the most frequently reported side effects in women

• Breast tenderness or enlargement

• Dizziness or light-headedness, particularly on standing (postural hypotension)

• Increased urinary frequency, due to its diuretic action

• Fatigue or headache

• Hyperkalaemia (elevated potassium levels): a potentially serious complication, particularly in those with renal impairment or those taking other medications that raise potassium

Less common but serious adverse effects include severe cutaneous reactions and, rarely, hepatotoxicity; patients should seek prompt medical attention if they develop a widespread rash, jaundice, or abdominal pain.

Patients should be advised to contact their GP promptly if they experience:

• Muscle weakness, cramps, or palpitations (possible signs of electrolyte imbalance)

• Significant dizziness or fainting

• Swelling of the face, lips, or throat (signs of allergic reaction)

• Any missed or significantly altered menstrual periods, particularly if pregnancy is possible

Spironolactone is contraindicated in pregnancy, in women with significant renal impairment (eGFR below 30 mL/min/1.73 m²), Addison's disease, or pre-existing hyperkalaemia. It should be used with caution alongside ACE inhibitors, ARBs, trimethoprim, co-trimoxazole, heparins, ciclosporin, tacrolimus, and other potassium-sparing agents (see Dosage section).

Off-label prescribing of spironolactone for hair loss should be accompanied by a clear discussion of risks and benefits, with the clinician's reasoning and the patient's informed consent documented in the medical record, in accordance with GMC guidance on prescribing unlicensed and off-label medicines.

Patients are encouraged to report any suspected side effects via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk). This helps the MHRA monitor the safety of medicines used in the UK.

Key UK references: emc SmPC for spironolactone; BNF: Spironolactone; NHS Medicines A–Z: Spironolactone; GMC Good practice in prescribing and managing medicines and devices; MHRA Yellow Card scheme.

Alternatives and Complementary Treatments Available on the NHS

Topical minoxidil is the recommended first-line treatment for female-pattern hair loss; oral minoxidil, co-cyprindiol, and — in post-menopausal women — finasteride or dutasteride may be considered under specialist supervision.

For women experiencing hair loss in the UK, spironolactone is one of several treatment options, and it is rarely the first intervention considered. NHS and NICE-aligned guidance generally supports a stepwise approach, beginning with the most established therapies.

Topical minoxidil (available over the counter as Regaine for Women) remains the most widely recommended first-line treatment for female-pattern hair loss. It works by prolonging the anagen (growth) phase of the hair cycle and improving follicular blood supply. A 2% or 5% solution or foam is applied directly to the scalp once or twice daily. Results typically become apparent after 3–6 months of consistent use.

Oral minoxidil at low doses (typically 0.5–2.5 mg daily) is increasingly being prescribed off-label by NHS dermatologists as an alternative for women who find topical application impractical or poorly tolerated. Evidence suggests it may be effective for some patients, though it carries its own side effect profile — including hypertrichosis (unwanted body hair growth), fluid retention, tachycardia, and postural hypotension — and requires appropriate monitoring, including blood pressure and heart rate checks.

For women with confirmed androgen excess or PCOS, co-cyprindiol (a combined oral contraceptive containing cyproterone acetate, an anti-androgen) may be considered by a specialist. It is licensed for acne and hirsutism rather than FPHL specifically, carries a higher risk of venous thromboembolism (VTE) than standard combined oral contraceptives, and is not suitable for all patients. Its use for hair loss is off-label and should be discussed carefully with a clinician.

In post-menopausal women, finasteride or dutasteride may occasionally be considered off-label under specialist supervision, with strict avoidance of pregnancy due to teratogenic risk. These agents are not appropriate for women of childbearing potential.

Beyond pharmacological options, patients may benefit from:

• Nutritional assessment: deficiencies in iron (ferritin), thyroid function, and — where clinically indicated — vitamin D, vitamin B12, or zinc can contribute to hair shedding and should be investigated and corrected. In UK primary care, a full blood count (FBC), ferritin, and thyroid function tests (TFTs) are typically the first-line investigations; further tests are guided by clinical history and examination

• Referral to a GP or NHS dermatologist for a comprehensive scalp assessment and to exclude other causes of hair loss

• Psychological support: hair loss can significantly affect mental wellbeing, and referral to counselling or support groups may be appropriate

Patients are encouraged to discuss all available options with their GP or specialist to determine the most suitable and evidence-based approach for their individual circumstances.

Key UK references: NHS hair loss (alopecia) page; PCDS Female Pattern Hair Loss guidance; BAD patient information on Female Pattern Hair Loss; BNF: Minoxidil; BNF: Co-cyprindiol.

Frequently Asked Questions